GLYPROLINE PEPTIDE PHARMACODYNAMICS IN RATS IN THE SETTING OF METABOLIC SYNDROME BY THE PARAMETERS OF LIPID METABOLISM AND TROMBOELASTOGRAMMA
https://doi.org/10.33647/2074-5982-15-4-58-66
Abstract
About the Authors
T. Yu. OberganRussian Federation
Cand. Sci. (Biol.),
119234, Moscow, Leninskie gory str., 1/12
M. G. Lyapina
Russian Federation
119234, Moscow, Leninskie gory str., 1/12
M. E. Grigorjeva
Russian Federation
Cand. Sci. (Biol.),
119234, Moscow, Leninskie gory str., 1/12
L. A. Lyapina
Russian Federation
119234, Moscow, Leninskie gory str., 1/12
References
1. Ashmarin I.P. Pathologicheskaja fi siologija i biochimia [Pathological physiology and biochemie]. Мoscow: Eksamen, 2005. 478 p. (In Russian).
2. Аshmarin I.P., Lyapina L.A., Andreeva L.A., Uljanov A.M., Pastorova V.E., Obergan T.Y., et al. Lechebnyi effect gliprolinov Pro-Gly i Pro-Gly-Pro pri rasvitii experimentalnogo insulinzavisimogo diabeta [Medical effect of glyproline Pro-Gly and Pro-Gly-Pro with the developnet of insulin-dependent diabetes]. Tromboz, gemostaz i reologia [Thrombos, Hemostas and Reology]. 2008;34(2):38–43. (In Russian).
3. Barkagan Z.S., Коstyuchenko G.I. Metabolicheski-vospalitelnaya kontseptsiya aterotromboza i novye podkhody k terapii bolnykh [Metabolic-infl ammatory concept of athe rothrombosis and new approaches to the treatment of patients]. Bulleten Sib. otd. Ros. akad. med. nauk [Bull. Siberian branch of the Academy of Med. Sciences]. 2006;2(120):132–138. (In Russian).
4. Kuznik B.I., Khavinson V.Ch., Tarnovskaya S.I., Linjkova N.S. Epigeneticheskoe deystvie regulyatornykh peptidov na tsitokonoviy profi l i sistemy gemostaza [Epigenetic effect of regulatory peptides on cytokine profi le and hemostatic system]. Vestnik gematologii [The Bulletin of Hematology]. 2013;9(2):29–33. (In Russian).
5. Коvaleva O.N., Kravchenko N.A., Ambrosova T.N. Metabolicheskii sindrom: problemy diagnostiki i prognosticheskie kriterii [Metabolic syndrome: diagnostic problems and prognostic criteria]. Vnutrennaya meditsina [Internal Medicine]. 2008;1(7):1–4. (In Russian).
6. Lyapina L.A., Grigorjeva M.E., Obergan T.Y., Shubina T.A. Teoreticheskie I prakticheskie voprosy izuchenia funktsionalnogo sostojania protivosvertivajuschey sistemy [Theoretical and practical issues of studying the functional state of the blood anticoagulation system]. Мoscow: Аdvansed Solutions Publ., 2012. 160 p. (In Russian).
7. Myasoedov N.F., Shubina T.A., Obergan T.Y., Grigorjeva M.E., Andreeva L.A., Lyapina L.A. Profi lakticheskoe gipokholesterinemicheskoe deytvie regulatornogo peptida Pro-Gly-Pro-Leu [Preventive hypocholesterolemic effect of regulatory peptide Pro-Gly-Pro-Leu]. Voprosy pitaniya [Problems of Nutrition]. 2013;82(5):41–45. (In Russian).
8. Andreeva L.A., Myasoedov N.F., Lyapina L.A., Grigor’eva M.E., Obergan T.Y., Shubina T.A. Effect of the PRO-GLY-PRO peptide on hemostasis and lipid metabolism in rats with hypercholesterolemia. Dokl. Biol. Sci. 2013;453(1):333–335.
9. Chiasson J.L., Josse R.G., Gomis R. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486–489.
10. Chew G.T., Gan S.K., Watts G.F. Revisiting the metabolic syndrome. MJA. 2006;185(8):445–449.
11. Day K. Metabolic syndrome, or what you will: defi - nitions and epidemiology. Diab. Vasc. Dis. Res. 2007;4(1):32–38.
12. Ikee R., Hamasaki Y., Oka M., Maesato K., Mano T., Moriya H., et al. Clinical: High-density lipoprotein cholesterol and left ventricular mass index in peritoneal dialysis. Perit. Dial. Int. 2008;28:611–616.
13. Jiao J., Han S.F, Zhang W., Xu J.Y., Tong X., Yin X.B., et al. Chronic leucine supplementation improves lipid metabolism in C57BL/6J mice fed with a high-fat/cholesterol diet. Food Nutr. Res. 2016;60:31–34.
14. Ilas J., Hudecz F., Süli-Vargha H., Kikelj D. Peptides and pseudopeptides incorporating D-Phe-Pro-Arg and Arg-Gly-Asp lead sequences as potential antithrombotic agents. J. Pept. Sci. 2008;14(8):946–953.
15. Kong X., Zhang D.Y., Wu H.B., Li F.X. Losartan and pioglitazone ameliorate nephropathy in experimental metabolic syndrome rats. Biol. Pharm. Bull. 2011;34(5):693–698.
16. Myasoedov N.F., Lyapina L.A., Grigorjeva M.E., Obergan T.Y., Shubina T.A., Andreeva L.A. Мechanism for glyproline protection in hypercholesterolemia. Pathophysiol. 2016;23(1):27–33.
17. Preetha P.P., Devi В.G., Rajamohan Т. Mature coconut water exhibits antidiabetic and antithrombotic potential via L-arginine-nitric oxide pathway in alloxan induced diabetic rats. J. Basic. Clin. Physiol. Pharmacol. 2015;26(6):575–583.
18. Watson T., Arya A., Sulke N., Lip G.Y.H. Antithrombotic therapy: relationship of indices of infl ammation and thrombogenesis to arithmia burden in paroxysmal arterial fi brillation. Chest. 2010;137:869–876.
19. Xiao C., Hsieh J., Adeli K., Lewis G.F. Gut-liver interaction in trig lyceride-rich lipoprotein metabolism. Am. J. Physiol. Endocrin. Metab. 2011;301:E429–E446.
Review
For citations:
Obergan T.Yu., Lyapina M.G., Grigorjeva M.E., Lyapina L.A. GLYPROLINE PEPTIDE PHARMACODYNAMICS IN RATS IN THE SETTING OF METABOLIC SYNDROME BY THE PARAMETERS OF LIPID METABOLISM AND TROMBOELASTOGRAMMA. Journal Biomed. 2019;(4):58-66. (In Russ.) https://doi.org/10.33647/2074-5982-15-4-58-66